Preventing Influenza in Older Adults: A Closer Look at Adjuvanted Vaccines

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Preventing Influenza in Older Adults: A Closer Look at Adjuvanted Vaccines



ReachMD Healthcare Image

How can adjuvanted vaccines help us relieve the burden of influenza disease in adults aged 65 and older? Let’s take a look at the data. 

Please See

Important Safety Information

  • Sponsored by

  • Overview

    As we age, our immune system becomes weaker and is therefore unable to ward off infection as easily as in our younger years.1 This is particularly troublesome during flu season. In fact, the CDC’s Advisory Committee on Immunization Practices (ACIP) recently looked at flu vaccine data for adults aged 65 years and older, and they now recommend that this age group preferentially receive higher dose or adjuvanted vaccines over standard dose unadjuvanted vaccines when available.2 So what was the data that led to these updated recommendations? Joining Dr. Matt Birnholz to share those key findings and the role of adjuvanted vaccines like FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) in preventing influenza in older adults is Dr. David Canaday, Professor in the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University in Cleveland.

    Avoid use in patients who have experienced any severe allergic reactions to any component of the vaccine. For more risk information please see below or consult the Full US Prescribing Information for FLUAD® QUADRIVALENT here.

    1. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659-666.
    2. Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden. Accessed April 23, 2021.

    USA-FLUD-22-0041 September 2022

  • Fluad® Quadrivalent (Influenza Vaccine, Adjuvanted)


    FLUAD® QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD® QUADRIVALENT is approved for use in persons 65 years of age and older.

    This indication is approved under accelerated approval based on the immune response elicited by FLUAD® QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

    If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD® QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

    Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

    The immune response to FLUAD® QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

    Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD® QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

    FLUAD® QUADRIVALENT administered by needle and syringe:

    The most common (≥ 10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

    Other adverse events may occur. For a comprehensive list of local and systemic adverse reactions, please see full prescribing information.

    To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1- 855-358-8966 or VAERS at 1-800-822-7967 and

Schedule8 Jun 2023